Isomorphic Labs Raises $5 Billion in Series C for AI Drug Design
Isomorphic Labs, the Alphabet drug discovery company led by Demis Hassabis, raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, according to The Next Web. Andreessen Horowitz and other new investors joined, while Alphabet and existing investors participated; the company said the round was oversubscribed, but no independent evidence was supplied. Isomorphic plans to use the funding to advance IsoDDE toward clinical trials, expand into additional drug modalities and support more than 20 programmes.
The financing provides substantial capital for Isomorphic Labs’ AI drug-design platform and clinical development, while the company’s valuation remains undisclosed and is only externally estimated at about $50 billion.

Isomorphic Labs, the Alphabet drug discovery company run by Demis Hassabis, has raised $5bn in a Series C round co-led by Greenoaks and Sequoia Capital. The company announced the round on Tuesday, six months after it raised $2.1bn in May.
#Isomorphic Labs#Alphabet#Greenoaks#Sequoia Capital#Andreessen Horowitz#Thrive Capital#MGX#GV#CapitalG#Temasek#UK Sovereign AI Fund#IsoDDE